Original Article

Co-occurring Gastrointestinal Symptoms Are Associated With Taste Changes in Oncology Patients Receiving Chemotherapy

Alissa Nolden, PhD, Paule V. Joseph, RN, PhD, Kord M. Kober, PhD, Bruce A. Cooper, PhD, Steven M. Paul, PhD, Marilyn J. Hammer, RN, PhD, Laura B. Dunn, MD, Yvette P. Conley, PhD, Jon D. Levine, MD, PhD, and Christine Miaskowski, RN, PhD

Food Science Department (A.N.), College of Natural Sciences, University of Massachusetts, Amherst, Massachusetts; Sensory Science & Metabolism Unit (P.V.J.), Biobehavioral Branch, Division of Intramural Research, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Department of Physiological Nursing, (K.M.K., B.A.C., S.M.P., C.M.), School of Nursing, University of California San Francisco, San Francisco, California; Department of Nursing (M.J.H.), Mount Sinai Medical Center, New York, New York; School of Medicine (L.B.D.), Stanford University, Stanford, California; School of Nursing (Y.P.C.), University of Pittsburgh, Pittsburgh, Pennsylvania; and School of Medicine (J.D.L.), University of California, San Francisco, California, USA

Abstract

Context. Over 80% of patients with cancer report taste changes. Despite the high prevalence of this symptom and its negative effects on health, few studies have assessed its association with other gastrointestinal (GI) symptoms.

Objectives. Determine the occurrence, frequency, severity, and distress of patient-reported "change in the way food tastes" (CFT) and identify phenotypic and GI symptoms characteristics associated with its occurrence.

Methods. Patients receiving chemotherapy for breast, GI, gynecological, or lung cancer completed demographic and symptom questionnaires prior to their second or third cycle of chemotherapy. CFT was assessed using the Memorial Symptom Assessment Scale. Differences in demographic, clinical, and GI symptom characteristics were evaluated using parametric and nonparametric tests.

Results. Of the 1329 patients, 49.4% reported experiencing CFT in the week prior to their second or third cycle of chemotherapy. In the univariate analysis, patients who reported CFT had fewer years of education; were more likely to be black or Hispanic, mixed race, or other; and had a lower annual household income. A higher percentage of patients with CFT reported the occurrence of 13 GI symptoms (e.g., constipation, diarrhea, abdominal cramps, feeling bloated). In a multivariable logistic regression analysis, compared with patients with breast cancer, patients with lung cancer (odds ratio = 0.55; $P = 0.004$) had a decrease in the odds of being in the CFT group. Patients who received a neurokinin-1 receptor antagonist and two other antiemetics were at an increased odds of being in the CFT group (odds ratio = 2.51; $P = 0.001$). Eight of the 13 GI symptoms evaluated were associated with an increased odds of being in the CFT group.

Conclusions. This study provides new evidence on the frequency, severity, and distress of CFT in oncology patients undergoing chemotherapy. These findings suggest that CFT is an important problem that warrants ongoing assessments and nutritional interventions. J Pain Symptom Manage 2019;58:756−765. © 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Key Words
Taste changes, chemotherapy, symptoms, nausea, constipation, diarrhea

Introduction

Taste changes occur in up to 84% of patients undergoing chemotherapy.[1] The sense of taste is vital for nutritional intake and food choices.[2] These changes begin within weeks of starting chemotherapy[3] and recover approximately 8 weeks after the completion of therapy.[4] However, changes can persist for years after treatment.[5] Taste changes may involve a decrease in taste sensitivity (hypogeusia), an absence of taste sensation (ageusia), an alteration in normal taste (dysgeusia), or the occurrence of a taste perception without an external stimulus (phantogeusia).[6] If the sense of taste and perception of food flavors are altered, patients may experience decrements in nutritional status and weight loss.[7] These taste changes and nutritional deficits are associated with poorer responses to treatment as well as increases in adverse effects, morbidity, and mortality.[8,9] Despite the clinical importance of taste changes, they are often overlooked by clinicians, and studies of this symptom in patients receiving chemotherapy are limited.

An increased understanding of the phenotypic characteristics associated with changes in the way food tastes may identify modifiable risk factors. Findings from the general population suggest that age, sex, and race influence taste perceptions.[10,11] For example, in two studies that used data from the U.S. National Health and Nutrition Examination Study,[12,13] in adults older than 40 years, the prevalence of taste dysfunction decreased with age in women, but not in men. In addition, taste impairment was greater among non-Hispanic Black Americans than among other ethnic groups.[12] Other factors associated with self-reported taste alterations included: lower level of education, xerostomia, fair/poor health, and nose/facial injury.[13]

In terms of patients receiving chemotherapy, while several studies reported no relationships,[14–20] in four studies,[21–24] self-reported taste changes were more prevalent among women, younger patients, and those with higher levels of education. In contrast, patients who smoked or abused alcohol reported fewer taste changes.[22]

With regards to clinical characteristics, several studies reported no associations between taste changes and a variety of clinical characteristics (e.g., cancer diagnosis, time since diagnosis, chemotherapy regimen, prior cancer treatments).[15–18,21,22] However, in one study of patients with lung, pancreatic, and colon cancer, compared with patients with the other two diagnoses, patients with colon cancer reported more severe taste alterations.[22] In another study of patients with heterogeneous cancer diagnoses, prevalence rates for taste changes were highest among patients with colon cancer, followed by breast, lung, and lymphoma cancers.[23] In terms of specific chemotherapy drugs, in one study,[22] the highest rates of taste alterations were reported by patients who received irinotecan, followed by FOLFOX (i.e., 5-fluorouracil, leucovorin, and oxaliplatin) and gemcitabine. In another study,[21] the highest percentages of dysgeusia were associated with regimens that contained antimetabolites with platinum derivatives and antimetabolites with cytotoxic antibiotics. These inconsistent findings may be related to a number of factors including sample size, timing of the assessments, and methods used to evaluate taste changes (e.g., objective vs. subjective measures).

Information on the co-occurrence of other gastrointestinal (GI) symptoms may provide additional insights into the occurrence of taste changes in patients receiving chemotherapy. While the oral cavity gives rise to the perceptions of taste, as well as the flavors of foods and beverages, it is only the beginning of the digestive system that is impacted by chemotherapy. Only two studies were found that evaluated for associations between taste changes and four GI symptoms (i.e., nausea/vomiting, appetite loss, constipation, diarrhea) in patients receiving chemotherapy.[23,25] Greater taste changes were associated with loss of appetite[23,25] and increased severity of nausea and vomiting.[23] A more in-depth analysis of the relationships between taste changes and other GI symptoms in patients receiving chemotherapy will provide increased insights into this clinically important problem. Given the paucity of research on this symptom, the purposes of the study, in a sample of oncology patients ($n = 1329$) receiving chemotherapy, were to determine the occurrence, frequency, severity, and distress associated with self-reported "change in the way food tastes" (CFT) and to identify phenotypic and GI symptom characteristics associated with its occurrence.

Methods

Patients and Settings

This analysis is part of a larger study, funded by the National Cancer Institute, that evaluated the symptom experience of oncology outpatients receiving chemotherapy.[26–28] Eligible patients were those aged ≥18 years; who had a diagnosis of breast, GI, gynecological, or lung cancer; who had received chemotherapy within the preceding four weeks; who were scheduled to receive at least two additional cycles of chemotherapy; who were able to read, write, and understand English; and who gave written informed consent. Patients were recruited from two comprehensive cancer centers, one Veteran's Affairs hospital and four community-based oncology programs. Of the

2234 patients approached, 1343 consented to participate. For this analysis, 1329 patients with data on CFT were included.

Instruments

A demographic questionnaire was used to obtain information on age, gender, ethnicity, marital status, living arrangements, education, employment status, and income. Patients completed the Karnofsky Performance Status (KPS) scale[29] and the Self-Administered Comorbidity Questionnaire[30] to evaluate functional status and comorbidity, respectively. The Alcohol Use Disorders Identification Test (AUDIT) was used to assess alcohol consumption, alcohol dependence, and the consequences of alcohol abuse in the last 12 months.[31,32]

The Memorial Symptom Assessment Scale (MSAS) was used to evaluate the occurrence, severity, frequency, and distress of 38 symptoms commonly associated with cancer and its treatment, including CFT. For this analysis, the following GI symptoms were evaluated: CFT, constipation, diarrhea, feeling bloated, abdominal cramps, difficulty swallowing, weight gain, weight loss, increased appetite, lack of appetite, mouth sores, dry mouth, vomiting, and nausea.

Using the MSAS, patients were asked to indicate whether or not they had experienced each symptom in the past week (i.e., symptom occurrence). If they had experienced the symptom, they were asked to rate its frequency of occurrence, severity, and distress. The validity and reliability of the MSAS are well established.[33]

Study Procedures

The study was approved by the Committee on Human Research at the University of California, San Francisco, and by the institutional review board at each of the study sites. Eligible patients were approached by a research staff member in the infusion unit during their first or second cycle of chemotherapy to discuss participation in the study. Written informed consent was obtained from all patients. Depending on the length of their chemotherapy cycles, patients completed questionnaires in their homes for a total of six times over two cycles of chemotherapy. For this analysis, symptom occurrence data from the enrollment assessment that asked patients to report on their symptom experience for the week prior to the administration of their second or third cycle of chemotherapy were analyzed (i.e., recovery from previous chemotherapy cycle). Medical records were reviewed for disease and treatment information.

Data Analysis

Data were analyzed using the SPSS version 23[34] and STATA version 14.[35] Descriptive statistics and frequency distributions were calculated for demographic, clinical, and symptom characteristics. MAX2 scores,[36,37] emetogenicity of the chemotherapy regimen, and antiemetic regimens were calculated as previously described.[38] Differences in demographics and clinical and symptom characteristics between patients who did and did not report CFT were evaluated using Independent sample t-tests, Chi-Square analyses, and Mann-Whitney U tests. To evaluate the association between select phenotypic and symptom characteristics and CFT group membership, a backwards, stepwise logistic regression analysis was performed. The initial logistic regression model included 11 phenotypic characteristics (i.e., education, ethnicity, KPS score, number of prior cancer treatments, number of metastatic sites, exercise on a regular basis, cancer diagnosis, type of prior cancer treatments, MAX2 score, cycle length, emetogenicity of chemotherapy regimen, antiemetic regimen) that differed between the two groups (Table 1) and the occurrence of the 13 GI symptoms on the MSAS. A *P*-value of <.05 was considered statistically significant.

Results

Sample Characteristics

Of the 1329 patients in this study, 49.4% reported experiencing CFT in the week prior to their second or third cycle of chemotherapy (Fig. 1A). Of these 656 patients, 21.7% (*n* = 141) rated the frequency of occurrence of CFT as "almost constantly" and 26.3% (*n* = 171) rated it as "frequently" (Fig. 1B). In terms of the severity of CFT, 45.4% (*n* = 292) rated it as "moderate" and 20.4% (*n* = 131) and 8.7% (*n* = 56) rated it as "severe" or "very severe," respectively (Fig. 1C). Over 25% of the patients reported "quite a bit" (13.5%; *n* = 86) or "very much" (12.9%; *n* = 82) distress from CFT (Fig. 1D).

Differences in Phenotypic and GI Symptom Characteristics

Patients who reported CFT had fewer years of education; were more likely to be black or Hispanic, mixed race, or other; and had a lower annual household income (Table 1). In addition, patients in the CFT group had lower KPS scores, were fewer years from their cancer diagnosis, had received fewer cancer treatments, and had fewer metastatic sites. Furthermore, a higher percentage of patients in the CFT group had breast cancer, had received chemotherapy on a 14-day cycle, had higher MAX2 scores, were receiving highly emetogenic chemotherapy, and were more likely to be receiving an antiemetic regimen that contained a neurokinin-1 (NK-1) receptor

Table 1
Differences in Demographic and Clinical Characteristics Between Patients With and Without Self-Reported Change in the Way Food Tastes (*n* = 1329)

Characteristic	No Taste Changes (0) 50.6% (*n* = 673) Mean (SD)	With Taste Changes (1) 49.4% (*n* = 656) Mean (SD)	Statistics
Age (years)	57.50 (12.50)	57.02 (12.15)	t = 0.72; P = 0.474
Education (years)	16.41 (3.09)	15.97 (2.94)	t = 2.66; P = 0.008
Body mass index (kg/m^2)	25.91 (5.31)	26.52 (6.02)	t = −1.94; P = 0.052
Karnofsky Performance Status score	81.97 (12.20)	78.10 (12.38)	t = 5.63; P < 0.001
Number of comorbidities	2.37 (1.41)	2.46 (1.46)	t = −1.19; P = 0.236
SCQ score	5.33 (3.03)	5.66 (3.36)	t = −1.85; P = 0.064
AUDIT score	3.12 (2.51)	2.82 (2.43)	t = 1.73; P = 0.084
Time since cancer diagnosis (years)	2.26 (4.23)	1.71 (3.50)	U; P = 0.037
Time since cancer diagnosis (median, years)	0.45	0.42	
Number of prior cancer treatments	1.70 (1.52)	1.48 (1.48)	t = 2.66; P = 0.008
Number of metastatic sites including lymph node involvement	1.32 (1.22)	1.16 (1.24)	t = 2.44; P = 0.015
Number of metastatic sites excluding lymph node involvement	0.86 (1.05)	0.71 (1.04)	t = 2.56; P = 0.011
MAX2 score	0.16 (0.08)	0.18 (0.08)	t = −4.01, P < .001
	% (n)	% (n)	
Gender[a]			χ^2 = 4.20; P = 0.122
Female	75.8 (510)	79.73 (523)	
Male	24.2 (163)	20.1 (132)	
Transgender	0.0 (0)	0.2 (1)	
Ethnicity			χ^2 = 19.14; P < 0.001
White	75.3 (499)	64.4 (418)	0 > 1
Black	5.6 (37)	8.9 (58)	0 < 1
Asian or Pacific Islander	10.7 (71)	13.9 (90)	NS
Hispanic, mixed, or other	8.4 (56)	12.8 (83)	0 < 1
Married or partnered (% yes)	66.2 (440)	62.5 (403)	FE, P = 0.167
Lives alone (% yes)	20.0 (133)	23.2 (150)	FE, P = 0.179
Childcare responsibilities (% yes)	20.1 (133)	23.9 (153)	FE, P = 0.108
Care of adult responsibilities (% yes)	6.7 (41)	9.1 (54)	FE, P = 0.164
Currently employed (% yes)	35.7 (238)	34.6 (224)	FE, P = 0.686
Income			
<$30,000	17.0 (102)	19.9 (117)	
$30,000 to <$70,000	20.1 (121)	22.2 (131)	
$70,000 to <$100,000	15.6 (94)	17.8 (105)	
≥$100,000	47.3 (284)	40.1 (236)	U, P = 0.020
Specific comorbidities (% yes)			
Heart disease	5.5 (37)	6.1 (40)	FE, P = 0.725
High blood pressure	29.6 (199)	31.4 (206)	FE, P = 0.475
Lung disease	12.8 (86)	9.8 (64)	FE, P = 0.084
Diabetes	9.2 (62)	9.0 (59)	FE, P = 0.924
Ulcer or stomach disease	4.0 (27)	5.6 (37)	FE, P = 0.200
Kidney disease	1.5 (10)	1.4 (9)	FE, P = 1.000
Liver disease	6.2 (42)	6.7 (44)	FE, P = 0.739
Anemia or blood disease	11.1 (75)	13.6 (89)	FE, P = 0.183
Depression	19.5 (131)	18.9 (124)	FE, P = 0.835
Osteoarthritis	11.3 (76)	13.3 (87)	FE, P = 0.278
Back pain	23.9 (161)	27.7 (182)	FE, P = 0.117
Rheumatoid arthritis	2.8 (19)	3.7 (24)	FE, P = 0.440
Exercise on a regular basis (% yes)	74.1 (492)	67.6 (430)	FE, P = 0.010
Smoking current or history of smoking (% yes)	36.8 (245)	33.8 (217)	FE, P = 0.272
Cancer diagnosis			χ^2 = 16.57; P = 0.001
Breast	36.0 (242)	44.5 (292)	0 < 1
Gastrointestinal	30.2 (203)	31.1 (204)	NS
Gynecological	20.7 (139)	14.3 (94)	0 > 1
Lung	13.2 (89)	10.1 (66)	NS

(*Continued*)

Table 1
Continued

	% (n)	% (n)	
Type of prior cancer treatment			$\chi^2 = 13.27; P = 0.004$
No prior treatment	23.1 (151)	26.9 (172)	NS
Only surgery, CTX, or RT	39.8 (260)	44.3 (283)	NS
Surgery & CTX, or Surgery & RT, or CTX & RT	23.7 (155)	16.0 (102)	0 > 1
Surgery & CTX & RT	13.3 (87)	12.8 (82)	NS
CTX cycle length			$\chi^2 = 11.71; P = 0.003$
14-Day cycle	38.2 (257)	46.0 (301)	0 < 1
21-Day cycle	52.7 (354)	48.5 (317)	NS
28-Day cycle	9.1 (61)	5.5 (36)	0 > 1
Emetogenicity of CTX			$\chi^2 = 16.41; P < 0.001$
Minimal/low	22.1 (149)	16.8 (110)	0 > 1
Moderate	62.4 (420)	59.6 (390)	NS
High	15.5 (104)	23.5 (154)	0 < 1
Antiemetic regimens			$\chi^2 = 37.27; P < 0.001$
None	9.1 (60)	5.0 (32)	0 > 1
Steroid alone or serotonin receptor antagonist alone	22.2 (146)	18.6 (119)	NS
Serotonin receptor antagonist and steroid	50.7 (333)	44.6 (285)	NS
NK-1 receptor antagonist and two other antiemetics	18.0 (118)	31.8 (203)	0 < 1

SD = standard deviation; kg = kilograms; m^2 = meter squared; SCQ = Self-administered Comorbidity Questionnaire; AUDIT = Alcohol Use Disorders Identification Test; U = Mann Whitney *U* test; χ^2 = Chi-squared test; NS = not significant; FE = Fisher's Exact test; CTX = chemotherapy; RT = radiation therapy; NK-1 = Neurokinin-1.

[a]Chi-squared test done without the transgender participant.

antagonist and two other antiemetics (e.g., serotonin [5HT3] receptor antagonist, steroid). Compared with the no CFT group, patients in the CFT group were less likely to exercise on a regular basis; less likely to have gynecological cancer; less likely to have received surgery and chemotherapy, surgery and radiation therapy, or chemotherapy and radiation; less likely to received chemotherapy on an 28-day cycle; less likely to have received minimal/low emetogenic chemotherapy, and more likely to have received an antiemetic.

With regard to the GI symptoms, a higher percentage of patients in the CFT group reported constipation, diarrhea, feeling bloated, abdominal cramps, difficulty swallowing, weight gain, weight loss, increased appetite, lack of appetite, mouth sores, dry mouth, vomiting, and nausea (Fig. 2).

Phenotypic and GI Symptom Characteristics Associated with CFT

The overall results of the logistic regression analysis were significant ($\chi^2 = 257.55$, $P < 0.001$; Table 2). None of the demographic characteristics were associated with CFT group membership. In terms of clinical characteristics, compared with patients with breast cancer, patients with lung cancer (odds ratio = 0.55; $P = 0.004$) had a decrease in the odds of being in the CFT group. In terms of antiemetic regimen, compared with patients who did not receive any antiemetic, patients who received an NK-1 receptor antagonist and two other antiemetics were at an increased

odds of being in the CFT group (odds ratio = 2.51; $P = 0.001$). Eight of the 11 GI symptoms evaluated were significantly associated with an increased odds of being in the CFT group.

Discussion

This study is the first and largest to describe phenotypic and GI symptom characteristics associated with CFT in patients with cancer after at least one cycle of chemotherapy. Consistent with previously reported prevalence rates that ranged from 25%[39] to 80%,[40] almost 50% of our patients reported experiencing CFT in the week prior to their second or third cycle of chemotherapy. In prior reports that used the MSAS,[41,42] the frequency of occurrence, as well as the severity, and distress related to CFT were highly variable. In terms of frequency, compared with the 21.7% of patients in our study who chose the rating "almost constantly," in a previous study,[42] only 11.5% of the patients used this rating. In terms of severity, compared with the 8.7% of our patients who rated CFT as severe or very severe, it ranged from 31.9%[41] to 36.8% in previous reports.[42] Finally, consistent with previous studies that found that between 18%[41] and 35%[43] of patients reported that CFT was "quite a bit or very much distressing", 26.4% of our patients used these ratings. These wide ranges in occurrence, frequency, severity, and distress ratings may be related to differences in phenotypic characteristics of the samples,

Fig. 1. Percentages of patients with and without self-reported change in the way food tastes (CFT, A) and distribution of patients' ratings of frequency (B), severity (C), and distress (D) associated with CFT.

heterogeneity in the types of cancer treatments the patients received, and stage of the patients' disease.

While in the univariate analysis, fewer years of education and ethnicity were associated with membership in the CFT group, none of the demographic characteristics remained significant in the multivariable model. While a higher percentage of African Americans reported taste alterations in a population-based study,[12] no studies were identified that found an association between ethnicity and CFT in oncology patients.

The only two clinical characteristics associated with CFT in the multivariable model were cancer diagnosis and antiemetic regimen. Compared with those with breast cancer, patients with lung cancer had a lower risk of being in the CFT group. While previous studies reported altered taste perceptions in patients with breast,[4,20,25,44] lung,[45,46] and gynecological[25,47] cancers, no studies were identified that examined relative risk of CFT across cancer diagnoses.

As noted in the Introduction, two studies identified differences in the prevalence of taste changes among various chemotherapy regimens.[21,22] Given the heterogeneity in cancer diagnoses and chemotherapy regimens in our study, we evaluated toxicity of the chemotherapy regimen (i.e., MAX2 score), the relative contribution of the emetogenicity of the chemotherapy regimen, cycle length, and the antiemetic regimen to membership in the CFT group. While all four characteristics were significant in the univariate analysis, only antiemetic regimen remained significant in the multivariable model.

In terms of the antiemetic regimen, being prescribed an NK-1 receptor antagonist with two other antiemetics (i.e., 5-HT-3 receptor antagonist being the most common additional antiemetic followed by a steroid) was associated with a 2.51-fold increased risk of being in the CFT group. Evidence exists to support a role for both of the agonists of the NK-1 (i.e., substance P) and 5-HT3 (i.e., serotonin) receptors in taste perception[48–53] and gut motility.[54–56] In terms of taste, NK-1 receptors are present in the gustatory center and taste papillae at substance P–sensitive nerve fibers.[57–59] The administration of an NK-1 receptor

Fig. 2. Differences in the occurrence rates for 13 gastrointestinal symptoms between patients who did and did not report change in the way food tastes.

antagonist blocked the release of substance P in a preclinical model.[49] In addition, taste buds release 5-HT directly in response to sour stimuli and indirectly in response to bitter and sweet tasting stimuli. In a

Table 2
Multiple Logistic Regression Analysis Predicting Change in the Way Food Tastes, Group Membership ($n = 1280$)

Predictor	Odds Ratio (95% CI)	P-Value
Cancer diagnosis		0.019
Gastrointestinal vs. breast	0.86 (0.63, 1.16)	0.313
Gynecological vs. breast	0.70 (0.49, 0.99)	0.046
Lung vs. breast	0.55 (0.36, 0.83)	0.004
Antiemetic regimen		0.001
Steroid alone or serotonin receptor antagonist alone vs. none	1.48 (0.86, 2.54)	0.160
Serotonin receptor antagonist and steroid vs. none	1.45 (0.87, 2.41)	0.149
NK-1 receptor antagonist and two other antiemetics vs. none	2.51 (1.47, 4.29)	0.001
Dry mouth	1.44 (1.11, 1.86)	0.006
Nausea	1.39 (1.07, 1.81)	0.014
Feeling bloated	1.34 (1.02, 1.77)	0.037
Lack of appetite	2.31 (1.76, 3.02)	<0.001
Increased appetite	1.56 (1.17, 2.08)	0.003
Difficult swallowing	1.87 (1.26, 2.78)	0.002
Mouth sores	1.57 (1.15, 2.16)	0.005
Constipation	1.50 (1.16, 1.94)	0.002
Overall model fit: degrees of freedom = 17; $\chi^2 = 257.55$, $P < .001$		

NK-1 = neurokinin 1.

preclinical study,[52] the administration of the 5-HT3 receptor antagonist, ondansetron, reduced taste nerve responses to acids and sucrose. Taken together, our findings are the first to suggest that multimodal antiemetic regimens, which are the standard of care for the treatment of chemotherapy-induced nausea and vomiting,[60,61] may contribute to taste changes in oncology patients undergoing chemotherapy.

In terms of their effects on gut motility, substance P plays a significant role in GI motility with resultant dysmotility, diarrhea, and edema.[62,63] In terms of 5-HT3, information on its role in gut motility is evolving. While exogenous 5HT-3 may stimulate GI motility, the role of endogenous 5HT-3 in GI motility is under active investigation.[55] However, the administration of NK-1 and 5-HT3 antagonists to patients receiving chemotherapy is associated with increased risk for constipation.[64–66] Finally, both NK-1 and 5HT-3 receptor antagonists act on regions of the brain that are involved in nausea, vomiting, and eating behaviors that overlap with gustatory pathways.[67,68] Therefore, it is possible that direct and indirect effects from both these antiemetics contribute to CFT during the administration of chemotherapy.

Our study is the first to evaluate the associations among common GI symptoms to CFT in patients undergoing chemotherapy. Consistent with our findings regarding the effects of the antiemetic regimen on taste and GI motility, in a recent review of studies of patients receiving primary or adjuvant chemotherapy,[69] a GI cluster was the most common symptom cluster identified. In studies that used the MSAS to evaluate for symptom clusters,[70–72] the most common symptoms across the various GI clusters identified were nausea, vomiting, lack of appetite, feeling bloated, and weight loss. In our study, CFT group membership was associated with dry mouth, nausea, feeling bloated, lack of appetite, increased appetite, difficulty swallowing, mouth sores, and constipation. The co-occurrence of these symptoms may be partially related to chemotherapy-induced alterations in the oral and intestinal mucosa.[73,74] For example, chemotherapy-induced alterations in taste are mediated by the sonic hedgehog pathway,[75,76] which disrupts taste cell renewal in the oral cavity through the inhibition of progenitor cells.[77,78] Undoubtedly, the mechanisms by which chemotherapy induces taste changes and co-occurring GI symptoms are extremely complex. In addition to the mechanisms cited previously, activation of proinflammatory and antiinflammatory pathways,[79] as well as alterations in the gut microbiome,[80,81] could alter taste perceptions. Finally, taste alterations could result in dietary changes that contribute to additional GI symptoms. Longitudinal studies are needed to examine the associations between CFT and co-occurring GI symptoms during chemotherapy.

Some limitations warrant consideration. While the sample size was large, only a single item was used to evaluate CFT. We acknowledge that CFT goes beyond the traditional definition of taste (i.e., sweet, sour, bitter, salty, and umami) and likely incorporates changes in flavor perception.[82,83] Therefore, studies that incorporate additional self-report measures, as well as quantitative psychophysical measures of taste, are needed to identify which taste qualities are affected and to confirm our findings on the associations between CFT and GI symptoms and antiemetic regimens. The combination of both subjective and objective measures of taste and smell functions would provide increased insights into patients' experiences and draw connections with food behaviors and nutritional status. Moreover, the present study focuses on a single time point during chemotherapy treatment. A prospective longitudinal study would allow for the exploration of the effects that chemotherapy and antiemetic regimens have on CFT and GI symptoms throughout treatment and during recovery. In addition, studies that explore the molecular mechanisms that underlie CFT would provide information on interindividual differences in this symptom in oncology patients. More information is needed to understand how CFT and GI symptoms influence changes in patients' food behaviors, dietary intake, and nutritional status.

In summary, while CFT is a severe and distressing symptom, clinicians fail to assess it and its associated impact on patients' nutritional status. Considering the high prevalence of CFT, ongoing assessment of this symptom is warranted. In addition, patients taking an NK-1 receptor antagonist as part of their antiemetic regimen may require additional symptom-management interventions because their CFT- and GI-related symptoms may be more severe.

Disclosure and Acknowledgment

References

1. Gamper E-M, Zabernigg A, Wintner LM, et al. Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manage 2012;44:880−895.

2. Kourouniotis S, Keast R, Riddell L, et al. The importance of taste on dietary choice, behaviour and intake in a group of young adults. Appetite 2016;103:1−7.

3. de Vries Y, Winkels R, van den Berg M, et al. Altered food preferences and chemosensory perception during chemotherapy in breast cancer patients: a longitudinal comparison with healthy controls. Food Qual Prefer 2018;63:135−143.

4. Boltong A, Aranda S, Keast R, et al. A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS One 2014;9:e103512.

5. Jensen SB, Mouridsen HT, Bergmann OJ, et al. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:217−226.

6. Amezaga J, Alfaro B, Rios Y, et al. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. Support Care Cancer 2018;26:4077−4086.

7. Kubrak C, Olson K, Jha N, et al. Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck 2010;32:290−300.

8. Pressoir M, Desné S, Berchery D, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 2010;102:966−971.

9. Arrieta O, Ortega RMM, Villanueva-Rodríguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non- small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010;10:50.

10. Hill CA, Beach M, Smith MC, Chen EY. Incidence of and factors associated with hypogeusia in healthy children. JAMA Otolaryngol Head Neck Surg 2016;142:229−233.

11. Williams JA, Bartoshuk LM, Fillingim RB, Dotson CD. Exploring ethnic differences in taste perception. Chem Senses 2016;41:449−456.

12. Liu G, Zong G, Doty RL, Sun QJBO. Prevalence and risk factors of taste and smell impairment in a nationwide representative sample of the US population: a cross-sectional study. BMJ Open 2016;6:e013246.

13. Rawal S, Hoffman HJ, Bainbridge KE, Huedo-Medina TB, Duffy VB. Prevalence and risk factors of self-reported smell and taste alterations: results from the 2011−2012 US National Health and Nutrition Examination Survey (NHANES). Chem Senses 2016;41:69−76.

14. Berteretche M, Dalix A, d'Ornano AC, et al. Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 2004;12:571−576.

15. Tantoy IY, Cooper BA, Dhruva A, et al. Changes in the occurrence, severity, and distress of symptoms in patients

with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manage 2018;55:808−834.

16. Brisbois TD, de Kock IH, Watanabe SM, Baracos VE, Wismer WV. Characterization of chemosensory alterations in advanced cancer reveals specific chemosensory phenotypes impacting dietary intake and quality of life. J Pain Symptom Manage 2011;41:673−683.

17. Sözeri E, Kutlutürkan S. Taste alteration in patients receiving chemotherapy. J Breast Health 2015;11:81.

18. Spotten L, Corish CA, Lorton C, et al. Subjective and objective taste and smell changes in cancer. Ann Oncol 2017;28:969−984.

19. IJpma I, Renken RJ, Gietema JA, et al. Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapy. Clin Nutr 2017;36:1642−1648.

20. Steinbach S, Hummel T, Bohner C, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 2009;27:1899−1905.

21. Bernhardson B-M, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008;16:275−283.

22. Zabernigg A, Gamper E-M, Giesinger JM, et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 2010;15:913−920.

23. Ponticelli E, Clari M, Frigerio S, et al. Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care 2017;26. https://doi.org/10.1111/ecc.12633.

24. Imai H, Soeda H, Komine K, Otsuka K, Shibata H. Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliat Care 2013;12:38.

25. Gamper EM, Giesinger JM, Oberguggenberger A, et al. Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: prevalence, course of severity, and quality of life correlates. Acta Oncol 2012;51:490−496.

26. Papachristou N, Puschmann D, Barnaghi P, et al. Learning from data to predict future symptoms of oncology patients. PloS one 2018;13:e0208808.

27. Kober KM, Cooper BA, Paul SM, et al. Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories. Support Care Cancer 2016;24:1473−1485.

28. Wright F, Melkus GDE, Hammer M, et al. Predictors and trajectories of morning fatigue are distinct from evening fatigue. J Pain Symptom Managet 2015;50:176−189.

29. Karnofsky D. Performance scale. New York: Plenum Press, 1977:301−307.

30. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156−163.

31. Babor TF, Higgins-Biddle J, Saunders J, Monteiro M. The alcohol use disorders identification test (AUDIT): Guidelines for use in primary care. World Health Organization, Department of Mental Health and Substance Abuse, 2001.

32. Babor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: the alcohol Use disorders Identification test: Guidelines for

Use in primary care. Geneva, Switzerland: World Health Organization, 1992.

33. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30:1326−1336.

34. IBM SPSS for Windows. Inc, 23 ed.. Armonk, NY: SPSS, Inc, 2015.

35. StataCorp. Stat Statistical Software. College Station, TX: Stata Corperation, 2015.

36. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 2012;118:3377−3386.

37. Extermann M, Reich RR, Sehovic M. Chemotoxicity recurrence in older patients: risk factors and effectiveness of preventive strategies-a prospective study. Cancer 2015; 121:2984−2992.

38. Singh KP, Kober KM, Dhruva AA, et al. Risk factors associated with chemotherapy- induced nausea in the week before the next cycle and impact of nausea on quality of life outcomes. J Pain Symptom Manage 2018;56:352−362.

39. Lam WWT, Law CC, Fu YT, et al. New insights in symptom assessment: the Chinese versions of the memorial symptom assessment scale short form (MSAS-SF) and the Condensed MSAS (CMSAS). J Pain Symptom Manage 2008;36:584−595.

40. Pud D. The psychometric properties of the Hebrew version of the Memorial Symptom Assessment Scale (MSAS-Heb) in patients with breast cancer. J Pain Symptom Manage 2015;49:790−795.

41. Cheng KK, Wong EM, Ling W, Chan CW, Thompson DR. Measuring the symptom experience of Chinese cancer patients: a validation of the Chinese version of the memorial symptom assessment scale. J Pain Symptom Manage 2009;37:44−57.

42. Yildirim Y, Tokem Y, Bozkurt N, et al. Reliability and validity of the Turkish version of the memorial symptom assessment scale in cancer patients. Asian Pac J Cancer Prev 2011; 12:3389−3396.

43. Webber K, Davies AN. Validity of the memorial symptom assessment scale-short form psychological subscales in advanced cancer patients. J Pain Symptom Manage 2011; 42:761−767.

44. de Vries YC, Boesveldt S, Kelfkens CS, et al. Taste and smell perception and quality of life during and after systemic therapy for breast cancer. Breast Cancer Res Treat 2018;170:27−34.

45. Belqaid K, Orrevall Y, McGreevy J, et al. Self-reported taste and smell alterations in patients under investigation for lung cancer. Acta Oncol 2014;53:1405−1412.

46. Belqaid K, Tishelman C, Orrevall Y, Mansson-Brahme E, Bernhardson BM. Dealing with taste and smell alterations-A qualitative interview study of people treated for lung cancer. PLoS One 2018;13:e0191117.

47. Nishijima S, Yanase T, Tsuneki I, Tamura M, Kurabayashi T. Examination of the taste disorder associated with gynecological cancer chemotherapy. Gynecol Oncol 2013;131:674−678.

48. Dill MJ, Shaw J, Cramer J, Sindelar DK. 5-HT1A receptor antagonists reduce food intake and body weight by reducing

total meals with no conditioned taste aversion. Pharmacol Biochem Behav 2013;112:1—8.

49. Grant J. Tachykinins stimulate a subset of mouse taste cells. PLoS One 2012;7:e31697.

50. Huang AY, Wu SY. Substance P as a putative efferent transmitter mediates GABAergic inhibition in mouse taste buds. Br J Pharmacol 2018;175:1039—1053.

51. Jaber L, Zhao FL, Kolli T, Herness S. A physiologic role for serotonergic transmission in adult rat taste buds. PLoS One 2014;9:e112152.

52. Larson ED, Vandenbeuch A, Voigt A, et al. The role of 5-HT3 receptors in signaling from taste buds to nerves. J Neurosci 2015;35:15984—15995.

53. Onaga T. Tachykinin: recent developments and novel roles in health and disease. Biomol Concepts 2014;5:225—243.

54. Ge X, Pan J, Liu Y, et al. Intestinal crosstalk between microbiota and serotonin and its impact on gut motility. Curr Pharm Biotechnol 2018;19:190—195.

55. Keating DJ, Spencer NJ. What is the role of endogenous gut serotonin in the control of gastrointestinal motility? Pharmacol Res 2019;140:50—55.

56. Neuhuber W, Worl J. Monoamines in the enteric nervous system. Histochem Cell Biol 2018;150:703—709.

57. Kinnman E, Aldskogius H. The role of substance P and calcitonin gene-related peptide containing nerve fibers in maintaining fungiform taste buds in the rat after a chronic chorda tympani nerve injury. Exper Neurol 1991;113:85—91.

58. Nagy J, Goedert M, Hunt S, Bond A. The nature of the substance P-containing nerve fibres in taste papillae of the rat tongue. Neuroscience 1982;7:3137—3151.

59. Chang GQ, Vigna SR, Simon SA. Localization of substance P NK-1 receptors in rat tongue. Regul Pept 1996;63:85—89.

60. Molassiotis A, Aapro M, Herrstedt J, Gralla R, Roila F. MASCC/ESMO antiemetic guidelines: introduction to the 2016 guideline update. Support Care Cancer 2017;25: 267—269.

61. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27:v119—v133.

62. Holzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001;1:583—590.

63. Lecci A, Capriati A, Altamura M, Maggi CA. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006;126-127: 232—249.

64. Li Q, Wang W, Chen G, et al. Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting. Open Med 2018;13:29—34.

65. Li Q, Wu Y, Wang W, et al. Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer 2019. https://doi.org/10.1016/j. currproblcancer.2019.01.003. [Epub ahead of print].

66. Yuan DM, Li Q, Zhang Q, et al. Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic

review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 2016;17:1661—1675.

67. Harrison TA, Hoover DB, King MS. Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers. Brain Res Bull 2004;63:7—17.

68. Tuerke KJ, Limebeer CL, Fletcher PJ, Parker LA. Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5- HT(3) receptor in the posterior and anterior insular cortex. J Neurosci 2012;32:13709—13717.

69. Ward Sullivan C, Leutwyler H, Dunn LB, Miaskowski C. A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy. J Clin Nurs 2018;27:516—545.

70. Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Symptom Manage 2010;39:847—858.

71. Huang J, Gu L, Zhang L, et al. Symptom clusters in ovarian cancer patients with chemotherapy after surgery: a longitudinal survey. Cancer Nurs 2016;39:106—116.

72. Suwisith N, Hanucharururnkul S, Dodd M, et al. Symptom clusters and functional status of women with breast cancer. Thai J Nurs Res 2008;12:153—165.

73. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995—2025.

74. Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009;10:79—83.

75. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303—312.

76. Kumari A, Ermilov AN, Allen BL, et al. Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J Neurophys 2015;113: 1034—1040.

77. Iwatsuki K, Liu H-X, Grónder A, et al. Wnt signaling interacts with Shh to regulate taste papilla development. PNAS 2007;104:2253—2258.

78. Miura H, Barlow LA. Taste bud regeneration and the search for taste progenitor cells. Arch Ital Biol 2010;148:107.

79. Wang H, Zhou M, Brand J, Huang L. Inflammation and taste disorders: mechanisms in taste buds. Ann N Y Acad Sci 2009;1170:596—603.

80. Turner A, Veysey M, Keely S, et al. Interactions between bitter taste, diet and dysbiosis: consequences for appetite and obesity. Nutrients 2018;10. https://doi.org/10.3390/nu10101336.

81. Lyte M, Fodor AA, Chapman CD, et al. Gut microbiota and a selectively bred taste phenotype: a novel model of microbiome-behavior relationships. Psychosom Med 2016; 78:610—619.

82. Small DM, Prescott J. Odor/taste integration and the perception of flavor. Exper Brain Res 2005;166:345—357.

83. Boltong A, Keast R. The influence of chemotherapy on taste perception and food hedonics: a systematic review. Can Treat Rev 2012;38:152—163.